Bumetanide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Bumetanide: From Congestive Heart Failure to Acute Pulmonary Heart Disease
One-Sentence Summary
Bumetanide is a loop diuretic originally used to treat fluid overload (oedema) in congestive heart failure. The TxGNN model predicts it may be effective for acute pulmonary heart disease, but no clinical trials and only 5 publications (mostly general reviews of heart failure and diuretics) currently relate to this prediction. The evidence is indirect, and the prediction largely reflects the drug's similarity to its existing heart failure use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Congestive heart failure |
| Predicted New Indication | Acute pulmonary heart disease |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, bumetanide is a loop diuretic that inhibits the NKCC2 transporter in the thick ascending limb of the loop of Henle. This reduces preload and relieves volume overload.
Acute right-sided heart failure (acute cor pulmonale) involves congestion that diuretics may relieve. However, this is the same mechanism as the approved heart failure indication, not a genuinely new one. The high TxGNN score most likely reflects this similarity to heart failure rather than independent evidence in acute cor pulmonale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3304383 | 1987 | Clinical haemodynamic study | Br J Clin Pharmacol | IV bumetanide in 24 patients with acute exercise-induced or chronic heart failure reduced cardiac index and pulmonary artery occluded pressure |
| 6391889 | 1984 | Review | Drugs | Review of bumetanide's pharmacology and use in oedema from heart failure, hepatic and renal disease, and acute pulmonary congestion |
| 19142155 | 2009 | Review | Am J Ther | Management of acute heart failure and diuretic therapy |
| 19843838 | 2009 | Review | Ann Pharmacother | Comparison of loop diuretics (pharmacokinetics, safety, efficacy, cost) |
| 39366035 | 2024 | Cohort | Am J Emerg Med | Epidemiology of heart failure presentations to US emergency departments, 2016–2023 |
None of these studies addresses acute cor pulmonale specifically.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN01421P | BURINEX INJECTION 0.5 mg/ml | Injection | Not stated in the compiled data |
| SIN00718P | BURINEX TABLET 1 mg | Tablet | Not stated in the compiled data |
Safety Considerations
Package insert warnings and contraindications were not available in the compiled data, so please refer to the package insert for safety information. The following supplementary information is available:
- Disease associations flagged as contraindications (knowledge graph, not label text): liver disease, gallbladder disease, thrombocytopenia, potassium deficiency, diabetes mellitus, diabetic ketoacidosis, hyperuricaemia, hepatic coma, hepatic encephalopathy, anuria, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders, hearing disorders and auditory system disease.
- Drug Interactions: 100 interactions were identified. Examples among those reviewed include:
- Moderate: acarbose, metformin, alogliptin, albiglutide, acetohexamide (antidiabetic agents, possible effect on glucose control); hydrocortisone, dexamethasone, betamethasone, triamcinolone, beclomethasone (corticosteroids); amphotericin B formulations; omeprazole, rabeprazole; bupropion; morphine; bisacodyl.
- Minor: doxycycline, acetylsalicylic acid.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by general heart failure and loop diuretic literature and small, old haemodynamic studies, with no trials in acute cor pulmonale. Its mechanism overlaps with the already approved heart failure use, so it offers little new indication value.
To proceed, the following is needed:
- Studies or trials specific to acute pulmonary heart disease (acute cor pulmonale) populations
- Mechanism of action data from DrugBank
- Package insert warnings and contraindications from the HSA website
- Approved indication text for the two Singapore registrations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.